The second type of ICI targets either Programmed Death Receptor-1 (PD-1) on mature cytotoxic CD8+ T cells or its ligands PD-L1 and PD-L2 expressed by cancer cells, stromal cells, and immune cells in the tumour microenvironment. The gene discussed is CD274; the disease is neoplasm.